Mode
Text Size
Log in / Sign up

ENGAGE program shows feasibility and preliminary signal for participation after chronic stroke in pilot trial

ENGAGE program shows feasibility and preliminary signal for participation after chronic stroke in pi…
Photo by Tom Brown / Unsplash
Key Takeaway
Consider ENGAGE pilot data as preliminary support for feasibility; efficacy requires controlled trial confirmation.

This was a phase 2a, single-arm, multi-site pilot study evaluating the feasibility of the ENGAGE intervention for community-dwelling survivors of chronic stroke. The 6-week program involved 12 in-person and 9 virtual sessions co-facilitated by stroke survivor peer mentors and occupational therapy providers. Of 42 consented participants, 30 started the intervention, with 27 completing it (90% retention). Active engagement was 85%, and 87% reported very high satisfaction. No injuries or injurious falls were reported.

The primary outcome was feasibility, including retention, engagement, acceptability, satisfaction, and safety. A secondary outcome measured within-group change in community and social participation using the PROMIS Ability to Participate in Social Roles and Activities Scale. Analysis showed a medium within-group effect size (d = 0.38), though the 95% confidence interval was wide and included zero (-0.11, 0.94).

Key limitations stem from the pilot design: there was no comparator group, the sample size was small (n=30 starting intervention), and the confidence interval for the participation effect includes zero, indicating statistical uncertainty. The study did not report on serious adverse events, discontinuations, tolerability, follow-up duration, or funding/conflicts.

For practice, this pilot provides preliminary evidence that a peer-mentor and therapist co-facilitated program is feasible, acceptable, and safe in this population, with a signal for improving participation. However, the single-arm design and small sample preclude conclusions about efficacy or causality. The results support proceeding to a controlled trial to rigorously test the intervention's effectiveness.

Study Details

Study typePhase2
Sample sizen = 42
EvidenceLevel 3
Follow-up1.4 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Survivors of stroke report low levels of community and social participation, even years after stroke. ENGAGE is a community-based intervention that merges social learning, guided problem solving, and supervised practice to collaboratively identify, generate, and apply solutions to challenges with community and social participation after stroke. OBJECTIVE: We examined the feasibility, acceptability, and safety of ENGAGE and characterized within group changes in community and social participation outcomes. METHODS: Community-dwelling survivors of stroke, occupational therapy providers, and occupational therapy scientists partnered to co-design the essential and structural elements of ENGAGE, as well as to evaluate ENGAGE using a multi-site single-arm community-based phase 2a clinical trial design. The 6-week ENGAGE program was co-facilitated by survivors of stroke acting as peer mentors and occupational therapy provider through in-person (Phase I, 12 sessions) or virtual web conference meetings (Phase II, 9 sessions). Feasibility was assessed through participant retention, engagement, acceptability, satisfaction, and safety. Within group change was assessed through the PROMIS Ability to Participation in Social Roles and Activities Scale. RESULTS: Of the 42 participants providing consent, 38 were eligible, and 30 started the intervention program. Retention in the ENGAGE program was 90 % (n = 27). Of these, 85 % engaged actively, 87 % indicated very high satisfaction, and 0 % reported injuries or injurious falls. Participants achieved a medium within group effect size of change in community and social participation (d = 0.38, 95 % CI = -0.11, 0.94). CONCLUSIONS: ENGAGE appears to be a feasible and promising intervention to promote improvements in community and social participation in community-dwelling survivors of stroke.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.